Charles Homcy
Founder bei BRIDGEBIO PHARMA, INC.
Vermögen: 38 Mio $ am 31.03.2024
Profil
Charles J.
Homcy founded Portola Pharmaceuticals LLC in 2003, where he worked as Co-Chairman, President & Chief Executive Officer, Global Blood Therapeutics, Inc. in 2011, where he worked as Independent Director from 2012 to 2019, and BridgeBio Pharma, Inc. in 2015, where he is working as Lead Director & Chairman-Pharmaceuticals from 2020.
Dr. Homcy also founded Relay Therapeutics, Inc. and Maze Therapeutics, Inc., where he is working as Chairman from 2019.
Dr. Homcy also currently works at BridgeBio Pharma LLC, as Lead Director & Chairman-Chairman from 2020, CytomX Therapeutics Holdings LLC, as Director from 2012, Ambys Medicines, Inc., as Director, Population Health Investment Co., Inc., as Independent Director, The Johns Hopkins University, as Trustee, and Third Rock Ventures LLC, as Partner from 2010 to 2022.
Dr. Homcy also formerly worked at Cephalon, Inc., as Director in 2011, COR Therapeutics, Inc., as Director, Executive VP-Research & Development from 1998 to 2002, Millennium Pharmaceuticals, Inc., as Director from 2002 to 2008, Geron Corp., as Director, Kosan Biosciences, Inc., as Director from 2003 to 2008, Cytokinetics, Inc., as Director in 2008, MyoKardia, Inc., as Non-Employee Class II Director from 2013 to 2017, Topica Pharmaceuticals, Inc., as Director, Pliant Therapeutics, Inc., as Independent Director from 2015 to 2022, Wyeth Holdings LLC, as President-Medical Research, The Trustees of Columbia University in The City of New York, as Professor in 1995, The General Hospital Corp., as Principal in 1990, The University of California, San Francisco, as Professor, Lederle Laboratories, as President-Medical Research Division from 1990 to 1994, Harvard Medical School, as Associate Professor in 1990, Presbyterian Hospital, Inc., as Clinical Professor in 1995, and UCSF School of Medicine, as Clinical Professor.
Dr. Homcy received his undergraduate degree and doctorate degree from The Johns Hopkins University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
BRIDGEBIO PHARMA, INC.
0,67% | 16.02.2024 | 1 230 085 ( 0,67% ) | 38 Mio $ | 31.03.2024 |
Aktive Positionen von Charles Homcy
| Unternehmen | Position | Beginn |
|---|---|---|
| BRIDGEBIO PHARMA, INC. | Founder | 01.01.2015 |
| POPULATION HEALTH INVESTMENT CO., INC. | Director/Board Member | - |
BridgeBio Pharma LLC
 BridgeBio Pharma LLC BiotechnologyHealth Technology BridgeBio Pharma LLC engages in the discovery and development of pharmaceutical drugs for patients with genetic diseases. It offers transthyretin stabilizer, SHP2 inhibitor, KRAS inhibitor, Collagen 7 replacement, and S1P-lyase inhibitor. The company was founded by Neil Kumar and is headquartered in Palo Alto, CA. | Director/Board Member | 01.11.2018 |
Maze Therapeutics, Inc.
 Maze Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Maze Therapeutics, Inc. is a is a biopharmaceutical company, which engages in the development of portfolio of therapeutic candidates for a number of genetically defined diseases. It focuses on translating genetic insights into new medicines by utilizing an approach that combines the analysis of large-scale human genetics data, cutting-edge functional genomics, and an array of drug discovery approaches. The company was founded by Mark Daly, Aaron D. Gitler, Stephen Elledge, Sekar Kathiresan, and Jonathan S. Weissman in 2018 and is headquartered in San Francisco, CA. | Founder | - |
Ambys Medicines, Inc.
 Ambys Medicines, Inc. Pharmaceuticals: MajorHealth Technology Ambys Medicines, Inc. develops regenerative medicine therapies for serious liver diseases. The company was founded by Martin Burke, Markus Grompe, Juan Carlos Izpisua Belmonte and Holger Willenbring and is headquartered in South San Francisco, CA. | Director/Board Member | - |
| The Johns Hopkins University | Director/Board Member | - |
Third Rock Ventures LLC
 Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures LLC (Third Rock Ventures) is a venture capital firm founded in 2007 by Mark Levin, Robert Tepper, Kevin Starr and Nick Leschly. The firm is headquartered in Boston, Massachusetts. | Consultant / Advisor | 01.01.2010 |
CytomX Therapeutics Holdings LLC
 CytomX Therapeutics Holdings LLC Pharmaceuticals: MajorHealth Technology CytomX Therapeutics Holdings LLC engaged in the development of new generation targeted antibody therapeutics. The company was founded by Frederick W. Gluck on January 31, 2008 and is headquartered in Santa Barbara, CA. | Director/Board Member | 06.10.2010 |
Ehemalige bekannte Positionen von Charles Homcy
| Unternehmen | Position | Ende |
|---|---|---|
| PLIANT THERAPEUTICS, INC. | Director/Board Member | 16.06.2022 |
| ░░░░░░ ░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░░░░ ░░░░░░░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
Ausbildung von Charles Homcy
| The Johns Hopkins University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 5 |
|---|---|
| GERON CORPORATION | Health Technology |
| CYTOKINETICS, INCORPORATED | Health Technology |
| PLIANT THERAPEUTICS, INC. | Health Technology |
| RELAY THERAPEUTICS, INC. | Health Technology |
| BRIDGEBIO PHARMA, INC. | Health Technology |
| Private Unternehmen | 18 |
|---|---|
Wyeth Holdings LLC
 Wyeth Holdings LLC Chemicals: AgriculturalProcess Industries Wyeth Holdings LLC manufactures and distributes chemicals. The firm's chemical contains phosphate rock, calcium, lime, carbide and nitrogen which are used in fertilizers. The company was founded by Frank Washburn in 1907 and is headquartered in Wayne, NJ. | Process Industries |
Cephalon, Inc.
 Cephalon, Inc. Pharmaceuticals: MajorHealth Technology Cephalon, Inc. manufactures and distributes pharmaceutical products. It engages in the discovery and development of medicines for central nervous system disorders, pain, and cancer. The company was founded on August 24, 1987 by Frank Baldino, Jr. and is headquartered in Frazer, PA. | Health Technology |
COR Therapeutics, Inc.
 COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | Health Technology |
Millennium Pharmaceuticals, Inc.
 Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Health Technology |
Kosan Biosciences, Inc.
 Kosan Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Kosan Biosciences, Inc. develops drugs for cancer therapeutics. The company was founded in 1995 and is headquartered in New York, NY. | Health Technology |
Portola Pharmaceuticals LLC
 Portola Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Portola Pharmaceuticals, Inc. engaged in the development and commercialization of novel therapeutics in the areas of thrombosis, other hematologic disorders, and inflammation. It offers Andexxa and Bevyxxa medicines. The company was founded by Charles J. Homcy and David R. Philips on September 2, 2003 and is headquartered in South San Francisco, CA. | Health Technology |
MyoKardia, Inc.
 MyoKardia, Inc. Pharmaceuticals: MajorHealth Technology MyoKardia, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, commercialization, and development of therapies for the treatment of cardiovascular diseases. Its lead therapeutic candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin being developed for the treatment of hypertrophic cardiomyopathy (HCM). The company was founded by James A. Spudich, Jonathan G. Seidman, Christine Seidman, and Leslie Leinwand on June 8, 2012 and is headquartered in South San Francisco, CA. | Health Technology |
The General Hospital Corp.
 The General Hospital Corp. Hospital/Nursing ManagementHealth Services The General Hospital Corp. provides healthcare services. It offers diagnostic and therapeutic are in every specialty and subspecialty of medicine and surgery. The firm's care center provides cancer, digestive disorders, heart disease, transplantation and vascular medicine services. The company was founded in 1811 and is headquartered in Boston, MA. | Health Services |
Lederle Laboratories
 Lederle Laboratories Miscellaneous Commercial ServicesCommercial Services Part of Pfizer Inc., Lederle Laboratories is a private company that provides testing services. The company is based in Pearl River, NY. | Commercial Services |
CytomX Therapeutics Holdings LLC
CytomX Therapeutics Holdings LLC Pharmaceuticals: MajorHealth Technology CytomX Therapeutics Holdings LLC engaged in the development of new generation targeted antibody therapeutics. The company was founded by Frederick W. Gluck on January 31, 2008 and is headquartered in Santa Barbara, CA. | Health Technology |
Topica Pharmaceuticals, Inc.
 Topica Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Topica Pharmaceuticals, Inc. develops treatment for onychomycosis, or fungal infections of the nail and nail bed. Its prodycte, Luliconazole, a topical antifungal a topical antifungal agent used to tinea pedis. The company was founded in 2004 and is headquartered Los Altos, CA. | Health Technology |
| Presbyterian Hospital, Inc. | |
BridgeBio Pharma LLC
BridgeBio Pharma LLC BiotechnologyHealth Technology BridgeBio Pharma LLC engages in the discovery and development of pharmaceutical drugs for patients with genetic diseases. It offers transthyretin stabilizer, SHP2 inhibitor, KRAS inhibitor, Collagen 7 replacement, and S1P-lyase inhibitor. The company was founded by Neil Kumar and is headquartered in Palo Alto, CA. | Health Technology |
Ambys Medicines, Inc.
Ambys Medicines, Inc. Pharmaceuticals: MajorHealth Technology Ambys Medicines, Inc. develops regenerative medicine therapies for serious liver diseases. The company was founded by Martin Burke, Markus Grompe, Juan Carlos Izpisua Belmonte and Holger Willenbring and is headquartered in South San Francisco, CA. | Health Technology |
Maze Therapeutics, Inc.
Maze Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Maze Therapeutics, Inc. is a is a biopharmaceutical company, which engages in the development of portfolio of therapeutic candidates for a number of genetically defined diseases. It focuses on translating genetic insights into new medicines by utilizing an approach that combines the analysis of large-scale human genetics data, cutting-edge functional genomics, and an array of drug discovery approaches. The company was founded by Mark Daly, Aaron D. Gitler, Stephen Elledge, Sekar Kathiresan, and Jonathan S. Weissman in 2018 and is headquartered in San Francisco, CA. | Commercial Services |
Population Health Investment Co., Inc.
 Population Health Investment Co., Inc. Financial ConglomeratesFinance Population Health Investment Co., Inc. operates as a blank check company, which engages in effecting a merger, capital stock exchange, asset acquisition, stock purchase and reorganization or similar business combination with one or more businesses. It intends to focus on companies in the healthcare industry such as the therapeutics sector. The company was founded by Clive A. Meanwell and Ian C. Read on September 11, 2020 and is headquartered in New York, NY. | Finance |
Third Rock Ventures LLC
Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures LLC (Third Rock Ventures) is a venture capital firm founded in 2007 by Mark Levin, Robert Tepper, Kevin Starr and Nick Leschly. The firm is headquartered in Boston, Massachusetts. | Finance |
Global Blood Therapeutics, Inc.
 Global Blood Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases. The company was founded by Matthew P. Jacobson, Andrej Sali, Jack Taunton, Charles J. Homcy, Craig D. Muir, and David R. Phillips in February 2011 and is headquartered in South San Francisco, CA. | Health Technology |
